New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
09:25 EDTIPXL, PRGOPerrigo announces FDA approval of generic version of Astepro nasal spray
Perrigo (PRGO) announced that it has received final approval from the FDA on its Abbreviated New Drug Application for azelastine hydrochloride nasal spray. The ANDA involved contributions from both Perrigo and Impax Laboratories (IPXL), who will share certain costs and benefits of this product. Perrigo and Impax continue to be in first to file Hatch Waxman patent litigation with Meda Pharmaceuticals in the United States District Court for the District of New Jersey. Perrigo has commenced shipment of product to its customers. Annual sales were approximately $97M annually, as measured by Symphony Health Solutions.
News For PRGO;IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
08:08 EDTPRGOGalmed and Perrigo sign agreement for aramchol API production
Galmed (GLMD) has entered into a Manufacturing Services Agreement with Perrigo (PRGO) subsidiary Perrigo API Ltd. for the large-scale production of the active pharmaceutical ingredient of Galmed's product candidate, aramchol. The API produced pursuant to this agreement is expected to provide sufficient quantities of aramchol for Galmed's potential future Phase III clinical trials of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH. The agreement also provides Perrigo with the option to manufacture commercial supplies of the aramchol API in the future.
January 26, 2015
08:09 EDTIPXLImpax receives FDA approval for generic version of Lamictal tablets
Subscribe for More Information
January 20, 2015
11:16 EDTPRGOPerrigo management to meet with B. Riley
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use